USA flag logo/image

An Official Website of the United States Government

Ex Vivo Culture of Umbilical Cord Blood Stem Cells for Adult Transplantation

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
88651 		Program Year/Program:
2007 / SBIR
Agency Tracking Number:
HL087473 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
QUALITY BIOLOGICAL, INC.
QUALITY BIOLOGICAL, INC. 7581 LINDBERGH DRIVE GAITHERSBURG, MD 20879
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2007
Title: Ex Vivo Culture of Umbilical Cord Blood Stem Cells for Adult Transplantation
Agency: HHS
Contract: 1R44HL087473-01
Award Amount: $107,143.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall goal of this proposal is to delineate the ex vivo serum-free culture conditions to expand CD34+ cells derived from cryopreserved umbilical cord blood cells to levels that will support its use in the adult tr ansplant setting. The disadvantage of umbilical cord blood for adult transplants has been attributed to having too few long-term engrafting cells/hematopoietic stem cells in the cord blood. Studies presented herein suggest that this problem can be circumve nted based on 1) the development of a clinical grade serum-free medium designated especially for the ex vivo expansion of CD 34+ cells derived from cord blood, 2) the successful expansion of CD 34+ cells from cryopreserved umbilical cord blood to levels ad equate to support adult transplantation using the clinical grade serum-free medium with the early acting cytokines, Flt-3 ligand, stem cell factor, thrombopoietin, and Interleukin 6, and 3) the ability of these ex vivo cultured CD 34+ cells to engraft long -term in the fetal sheep model for human hematopoiesis. The Phase I milestone will be to repeat and extended these initial studies and assess the long-term engrafting ability of these cultured CD 34+ cells in increased numbers of animals and evaluate longe r culture periods. These critical results will form the basis of the Phase II proposal to determine if 1) the long-term engrafting cells are being expanded or maintained under these ex vivo serum-free culture conditions, 2) define the optimal culture perio d yielding high quality long-term engrafting cells, and 3) evaluate other cytokines in combination with the above cytokine platform. The ability to expand the long-term engrafting cells would be invaluable in the adult transplant setting. The efforts from this proposal will yield clinically relevant data on the optimal conditions necessary for use of cryopreserved cord blood for adult transplantation. . The products derived form this proposal will support the ex vivo culture of CD34+ cells derived from cryo preserved umbilical cord blood and the maintenance of these cells ability to engraft long-term. Since cord blood has few long-term engrafting cells /hematopoietic stem cells it can only be used for infant transplantation, not adult transplantation. The abi lity to develop a serum-free clinical grade culture system that will support the expansion of the long-term engrafting cells will facilitate the clinical use of these cells in adult transplants.

Principal Investigator:

Ronald L. Brown
3018409331
BROWNR@QUALITYBIOLOGICAL.COM

Business Contact:

Prescott B. Whitaker
Small Business Information at Submission:

QUALITY BIOLOGICAL, INC.
QUALITY BIOLOGICAL, INC. 7581 LINDBERGH DRIVE GAITHERSBURG, MD 20879

EIN/Tax ID: 521288264
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No